Skip to main content Accessibility help

Describing the dynamic translational science landscape through Core Voucher utilization

  • Elvira L. Liclican (a1), Scott G. Filler (a2), Jonathan Kaye (a3) (a4) and Christopher T. Denny (a5) (a6) (a7)



Core facilities play crucial roles in carrying out the academic research mission by making available to researchers advanced technologies, facilities, or expertise that are unfeasible for most investigators to obtain on their own. To facilitate translational science through support of core services, the University of California, Los Angeles Clinical and Translational Science Institute (UCLA CTSI) created a Core Voucher program. The underlying premise is that by actively promoting interplay between researchers and core facilities, a dynamic feedback loop could be established that could enhance both groups, the productivity of the former and the relevance of the latter. Our primary goal was to give translational investigators what they need to pursue their immediate projects at hand.


To implement this system across four noncontiguous campuses, open-source web-accessible software applications were created that were scalable and could efficiently administer investigator submissions and subsequent reviews in a multicampus fashion.


In the past five years, we have processed over 1400 applications submitted by over 750 individual faculty members across both clinical and nonclinical departments. In total, 1926 core requests were made in conjunction with 1467 submitted proposals. The top 10 most popular cores accounted for 50% of all requests, and the top half of the most popular cores accounted for 90% of all requests.


Tracking investigator demand provides a unique window into what are the high- and low-priority core services that best support translational research.


Corresponding author

C. T. Denny, MD, UCLA Clinical and Translational Science Institute, University of California, University of California Pediatrics, Hematology and Oncology BOX 951752, 10-240 Factor, Los Angeles, CA 90095-1752, USA. Email:


Hide All
1. Le, SQ, et al. A humoral immune response alters the distribution of enzyme replacement therapy in murine mucopolysaccharidosis type I. Molecular Therapy-Methods & Clinical Development 2017; 8: 4251. PMID: 29159202.
2. Lawrence, R, et al. Glycan-based biomarkers for mucopolysaccharidoses. Molecular Genetics and Metabolism 2014; 111(2): 7383. PMID: 23958290.
3. Kan, SH, et al. Behavioral deficits and cholinergic pathway abnormalities in male Sanfilippo B mice. Behavioural Brain Research 2016; 312: 265271. PMID: 27340089.
4. Kan, SH, et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proceedings of the National Academy of Sciences 2014; 111(41): 1487014875. PMID: 25267636.
5. Jiang, J, et al. Structure of Tetrahymena telomerase reveals previously unknown subunits, functions, and interactions. Science 2015; 350(6260): aab4070. PMID: 26472759.
6. CTSA program resources Help UCLA scientists visualize key enzyme in cancer and aging. Retrieved from Accessed June, 2016.
7. Committee to Review the Clinical and Translational Science Awards Program at the National Center for Advancing Translational Sciences, Board on Health Sciences Policy, Institute of Medicine; Leshner AI, Terry SF, Schultz AM, Liverman CT, editors. The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research. Washington (DC): National Academies Press (US), 2013. PMID: 24199260.


Type Description Title
Supplementary materials

Liclican et al. supplementary material
Table S1

 PDF (177 KB)
177 KB


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed